CHAD H. SWANSON, Ph.D.

Chad H. Swanson, Ph.D., has served as our Chief Development Officer since September 2024. He served as SVP, Head of Clinical Development from January 2023 to September 2024. Prior to joining Prothena, he held several positions of increasing responsibility at Eisai, Inc. from 2011 to December 2022, including as the International Project Team Leader for the lecanemab program, leading clinical development for the first Alzheimer’s disease therapy targeting amyloid beta to receive full approval from the U.S. Food and Drug Administration. Prior to that role, Dr. Swanson held clinical research roles at Schering Plough and Merck Research Laboratories, and discovery research roles culminating as the US Head of Neurochemistry roles at Lundbeck Research US, Inc. Dr. Swanson earned his B.S. from the University of Wisconsin-Madison and his Ph.D. from Medical University of South Carolina, while completing postdoctoral training at Eli Lilly and Co.